美国胃肠病学会-加拿大胃肠病学会临床实践指南:急性消化道出血及围内镜期抗凝药与抗血小板药的管理
该指南基于系统评价和GRADE方法,针对急性消化道出血及择期内镜场景下抗凝药与抗血小板药的管理提出推荐。急性出血时,建议反对对华法林患者给予新鲜冰冻血浆或维生素K,反对对DOACs患者给予PCC,反对血小板输注,反对停用二级预防的心脏ASA。择期内镜时,建议华法林继续使用而非暂时中断,DOACs暂时中断,DAPT暂时中断P2Y12抑制剂而继续ASA,反对中断ASA单药治疗。
要点
- 急性消化道出血时,华法林患者建议反对给予新鲜冰冻血浆或维生素K,DOACs患者建议反对给予PCC。
- 急性消化道出血时,抗血小板药物患者建议反对血小板输注,二级预防的心脏ASA建议反对停用。
- 择期内镜时,华法林建议继续使用而非暂时中断,DOACs建议暂时中断而非继续。
核心结论
- 该指南针对急性消化道出血及围内镜期抗凝药与抗血小板药管理提出推荐,部分场景证据不足无法推荐。
研究设计与样本
- 美国胃肠病学会与加拿大胃肠病学会基于预设临床问题的系统评价,采用GRADE方法制定推荐。
主要发现
- 急性消化道出血时,华法林患者建议反对给予新鲜冰冻血浆或维生素K,如需则建议PCC对比新鲜冰冻血浆。
- 急性消化道出血时,DOACs患者建议反对给予PCC;达比加群患者建议反对给予idarucizumab,利伐沙班或阿哌沙班患者建议反对给予andexanet alfa。
- 急性消化道出血时,抗血小板药物患者建议反对血小板输注;二级预防的心脏ASA建议反对停用,若已中断则建议在内镜确认止血当天恢复。
- 择期内镜时,华法林建议继续使用而非暂时中断(1-7天),但若因高消化道出血风险操作而停用,建议反对桥接抗凝,除非有机械心脏瓣膜。
- 择期内镜时,DOACs建议暂时中断而非继续;DAPT建议暂时中断P2Y12受体抑制剂而继续ASA;ASA单药建议反对中断。
关键数值与推荐
- 急性消化道出血华法林患者:建议反对给予新鲜冰冻血浆或维生素K;如需则建议PCC对比新鲜冰冻血浆。
- 急性消化道出血DOACs患者:建议反对给予PCC;达比加群患者建议反对给予idarucizumab;利伐沙班或阿哌沙班患者建议反对给予andexanet alfa。
- 急性消化道出血抗血小板药物患者:建议反对血小板输注;二级预防心脏ASA建议反对停用,若已中断建议内镜确认止血当天恢复。
- 择期内镜华法林患者:建议继续使用而非暂时中断(1-7天);若因高出血风险操作停用,建议反对桥接抗凝,除非有机械心脏瓣膜。
- 择期内镜DOACs患者建议暂时中断而非继续;DAPT建议暂时中断P2Y12抑制剂而继续ASA;ASA单药建议反对中断。
临床怎么用
- 急性消化道出血时,华法林患者不建议给予新鲜冰冻血浆或维生素K;DOACs患者不建议给予PCC;抗血小板药物患者不建议血小板输注。
- 急性消化道出血时,二级预防的心脏ASA不建议停用;若已中断,建议在内镜确认止血当天恢复。
- 择期内镜时,华法林建议继续使用而非暂时中断(1-7天);DOACs建议暂时中断。
- 择期内镜时,DAPT建议暂时中断P2Y12受体抑制剂而继续ASA;ASA单药建议反对中断。
局限性
- 急性消化道出血华法林患者中,PCC对比安慰剂的证据不足,无法推荐支持或反对。
- 择期内镜时,单用P2Y12抑制剂患者暂时中断P2Y12受体抑制剂的证据不足,无法推荐支持或反对。
- 抗凝药(华法林或DOACs)或P2Y12受体抑制剂患者术后当天恢复对比术后1-7天恢复的证据不足,无法提出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1-7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y12 receptor inhibitor for patients on a single P2Y12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1-7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y12 receptor inhibitor drugs because of insufficient evidence.
引用
- Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol. 2022. PMID: 35297395. doi:10.14309/ajg.0000000000001627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。